Larvol Delta - A-Phase-II-Exploratory-Study-of-Sacituzumab-Tirumotecan-Combined-With-Envafolimab-for-TROP2Positive-Advanced-Biliary-Tract-Cancers-Previously-Treated-With-FirstLine-Immunotherapy-Combined-With-Chemotherapy

Jiataile (sacituzumab tirumotecan) - Merck (MSD)

Enweida (envafolimab) - 3DMed, Ascletis

http://clinicaltrials.gov/ct2/show/NCT07729033

Jul 28, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next